MDGL

Madrigal Pharmaceuticals, Inc. Earnings

$425.14

Earnings Summary

Revenue	$212.8Mn
Net Profits	$-42.28Mn
Net Profit Margins	-19.87%

Highlights

Revenue:

Madrigal Pharmaceuticals, Inc.’s revenue jumped 1353.76% since last year same period to $212.8Mn in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 55.05% jump in its revenue since last 3-months.

Net Profits:

Madrigal Pharmaceuticals, Inc.’s net profit jumped 72.18% since last year same period to $-42.28Mn in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 42.27% jump in its net profits since last 3-months.

Net Profit Margins:

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped 98.09% since last year same period to -19.87% in the Q2 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 62.77% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Madrigal Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter	-3.36
EPS Estimate Current Year	-3.36

Highlights

EPS Estimate Current Quarter:

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -3.36 - a 7.44% jump from last quarter’s estimates.

EPS Estimate Current Year:

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -3.36.

Key Ratios

Key ratios of the Madrigal Pharmaceuticals, Inc. post its Q2 2025 earnings

Earning Per Share (EPS)	-1.9
Return on Assets (ROA)	-0.18
Return on Equity (ROE)	-0.36

Highlights

Earning Per Share (EPS):

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 73.24% since last year same period to -1.9 in the Q2 2025. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 73.24% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.36.